Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FlyteHealth vs Nova MD

FlyteHealth
Graded #363

Lower grade

vs+7.999999999999993
Nova MD
Graded #188

Higher grade

The verdict

Nova MD takes it — 66.6/100 to 58.6/100.

Nova MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNova MD +22
45
67
Dose & formulationNova MD +24
40
64
Clinical oversightFlyteHealth +1
83
82
Labs & monitoringFlyteHealth +19
73
54
FulfillmentNova MD +6
62
68
Contract termsEven
55
55
FlyteHealth · left barNova MD · right bar

The numbers

MetricFlyteHealthNova MD
WeighScore58.6/10066.6/100
GradeCC
Scorecard rank#363#188
SemaglutideNot disclosed$175/mo (compounded)
TirzepatideNot disclosed$225/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FlyteHealth

Graded #363 · C

Strengths

  • Care led by board-certified obesity-medicine physicians
  • Multidisciplinary team with NPs, dietitians, and care coordinators
  • Published outcomes of about 13 to 16 percent weight loss over 12 months
  • High GLP-1 medication adherence (around 86 percent in reported data)
  • Comprehensive cardiometabolic care beyond GLP-1 alone

Where it loses points

  • Distributed primarily via employers, payers, and health plans, not direct cash-pay
  • Access is largely gated behind employer or plan sponsorship
  • GLP-1 is prescribed only when appropriate, not guaranteed
  • Self-pay pricing is not publicly listed (contact required)
  • Less suited to consumers wanting fast direct-to-door GLP-1
Nova MD

Graded #188 · C

Strengths

  • On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
  • $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
  • $50 off first tirzepatide order shown publicly
  • Explicit microdose / low-dose program for both semaglutide and tirzepatide
  • Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy not named — only 'accredited facilities'
  • LegitScript certification not confirmed (only 'Licensed US Providers' claims)
  • Per-state availability not listed
  • Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard